COSMO PHARMACEUTICALS NV (C43.DE) Stock Fundamental Analysis
Europe - FRA:C43 - NL0011832936 - Common Stock
48.8 EUR
-1.2 (-2.4%)
Taking everything into account, C43 scores 8 out of 10 in our fundamental rating. C43 was compared to 54 industry peers in the Pharmaceuticals industry. C43 scores excellent points on both the profitability and health parts. This is a solid base for a good stock. An interesting combination arises when we look at growth and value: C43 is growing strongly while it also seems undervalued. Finally C43 also has an excellent dividend rating. This makes C43 very considerable for value and dividend and growth and quality investing!
1. Profitability
1.1 Basic Checks
In the past year C43 was profitable.
C43 had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: C43 reported negative net income in multiple years.
C43 had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
C43 has a Return On Assets of 20.60%. This is amongst the best in the industry. C43 outperforms 94.23% of its industry peers.
With a decent Return On Equity value of 26.74%, C43 is doing good in the industry, outperforming 76.92% of the companies in the same industry.
C43 has a better Return On Invested Capital (21.60%) than 88.46% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 20.6% | ||
| ROE | 26.74% | ||
| ROIC | 21.6% |
ROA(3y)6.94%
ROA(5y)4.44%
ROE(3y)9.26%
ROE(5y)6.02%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Profit Margin, with a value of 49.94%, C43 belongs to the top of the industry, outperforming 98.08% of the companies in the same industry.
In the last couple of years the Profit Margin of C43 has grown nicely.
Looking at the Operating Margin, with a value of 55.81%, C43 belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
In the last couple of years the Operating Margin of C43 has grown nicely.
C43's Gross Margin of 83.00% is amongst the best of the industry. C43 outperforms 86.54% of its industry peers.
In the last couple of years the Gross Margin of C43 has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 55.81% | ||
| PM (TTM) | 49.94% | ||
| GM | 83% |
OM growth 3Y48.45%
OM growth 5YN/A
PM growth 3Y14.46%
PM growth 5YN/A
GM growth 3Y18.94%
GM growth 5Y6.74%
2. Health
2.1 Basic Checks
C43 has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
C43 has less shares outstanding than it did 1 year ago.
Compared to 5 years ago, C43 has more shares outstanding
C43 has a better debt/assets ratio than last year.
2.2 Solvency
C43 has an Altman-Z score of 5.80. This indicates that C43 is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 5.80, C43 belongs to the top of the industry, outperforming 90.38% of the companies in the same industry.
C43 has a debt to FCF ratio of 0.01. This is a very positive value and a sign of high solvency as it would only need 0.01 years to pay back of all of its debts.
With an excellent Debt to FCF ratio value of 0.01, C43 belongs to the best of the industry, outperforming 98.08% of the companies in the same industry.
C43 has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.00, C43 belongs to the top of the industry, outperforming 94.23% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0.01 | ||
| Altman-Z | 5.8 |
ROIC/WACC2.81
WACC7.68%
2.3 Liquidity
A Current Ratio of 4.19 indicates that C43 has no problem at all paying its short term obligations.
C43's Current ratio of 4.19 is amongst the best of the industry. C43 outperforms 96.15% of its industry peers.
A Quick Ratio of 3.91 indicates that C43 has no problem at all paying its short term obligations.
C43 has a better Quick ratio (3.91) than 96.15% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.19 | ||
| Quick Ratio | 3.91 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 1315.29% over the past year.
Measured over the past years, C43 shows a very strong growth in Earnings Per Share. The EPS has been growing by 85.20% on average per year.
Looking at the last year, C43 shows a very strong growth in Revenue. The Revenue has grown by 187.55%.
C43 shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 33.68% yearly.
EPS 1Y (TTM)1315.29%
EPS 3Y85.2%
EPS 5YN/A
EPS Q2Q%551.15%
Revenue 1Y (TTM)187.55%
Revenue growth 3Y60.05%
Revenue growth 5Y33.68%
Sales Q2Q%165.79%
3.2 Future
Based on estimates for the next years, C43 will show a very strong growth in Earnings Per Share. The EPS will grow by 29.02% on average per year.
Based on estimates for the next years, C43 will show a very strong growth in Revenue. The Revenue will grow by 22.67% on average per year.
EPS Next Y-23.67%
EPS Next 2Y-48.85%
EPS Next 3Y-27.68%
EPS Next 5Y29.02%
Revenue Next Year-19.4%
Revenue Next 2Y-19.53%
Revenue Next 3Y-19.24%
Revenue Next 5Y22.67%
3.3 Evolution
Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
C43 is valuated cheaply with a Price/Earnings ratio of 5.98.
Compared to the rest of the industry, the Price/Earnings ratio of C43 indicates a rather cheap valuation: C43 is cheaper than 92.31% of the companies listed in the same industry.
When comparing the Price/Earnings ratio of C43 to the average of the S&P500 Index (26.06), we can say C43 is valued rather cheaply.
C43 is valuated reasonably with a Price/Forward Earnings ratio of 8.09.
Based on the Price/Forward Earnings ratio, C43 is valued cheaper than 84.62% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of C43 to the average of the S&P500 Index (32.73), we can say C43 is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.98 | ||
| Fwd PE | 8.09 |
4.2 Price Multiples
C43's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. C43 is cheaper than 96.15% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, C43 is valued cheaply inside the industry as 94.23% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 5.46 | ||
| EV/EBITDA | 3.83 |
4.3 Compensation for Growth
The excellent profitability rating of C43 may justify a higher PE ratio.
A cheap valuation may be justified as C43's earnings are expected to decrease with -27.68% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-48.85%
EPS Next 3Y-27.68%
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 3.85%, C43 has a reasonable but not impressive dividend return.
In the last 3 months the price of C43 has falen by -28.24%. A price decline artificially increases the dividend yield. It may be a sign investors do not expect the dividend to last.
Compared to an average industry Dividend Yield of 2.89, C43 pays a bit more dividend than its industry peers.
Compared to an average S&P500 Dividend Yield of 2.37, C43 pays a better dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.85% |
5.2 History
The dividend of C43 is nicely growing with an annual growth rate of 7.41%!
Dividend Growth(5Y)7.41%
Div Incr Years1
Div Non Decr Years1
5.3 Sustainability
24.09% of the earnings are spent on dividend by C43. This is a low number and sustainable payout ratio.
The dividend of C43 is growing, but earnings are growing more, so the dividend growth is sustainable.
DP24.09%
EPS Next 2Y-48.85%
EPS Next 3Y-27.68%
FRA:C43 (4/29/2025, 7:00:00 PM)
48.8
-1.2 (-2.4%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners12.98%
Inst Owner ChangeN/A
Ins Owners38.78%
Ins Owner ChangeN/A
Market Cap855.95M
Revenue(TTM)266.79M
Net Income(TTM)133.24M
Analysts84
Price Target104.72 (114.59%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.85% |
Yearly Dividend2
Dividend Growth(5Y)7.41%
DP24.09%
Div Incr Years1
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)1.53%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)2.22%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-13.87%
Revenue NY rev (3m)-12.84%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.98 | ||
| Fwd PE | 8.09 | ||
| P/S | 3.21 | ||
| P/FCF | 5.46 | ||
| P/OCF | 5.27 | ||
| P/B | 1.72 | ||
| P/tB | 6.01 | ||
| EV/EBITDA | 3.83 |
EPS(TTM)8.16
EY16.72%
EPS(NY)6.03
Fwd EY12.36%
FCF(TTM)8.94
FCFY18.31%
OCF(TTM)9.26
OCFY18.97%
SpS15.21
BVpS28.41
TBVpS8.12
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 20.6% | ||
| ROE | 26.74% | ||
| ROCE | 24.88% | ||
| ROIC | 21.6% | ||
| ROICexc | 28.38% | ||
| ROICexgc | 129.8% | ||
| OM | 55.81% | ||
| PM (TTM) | 49.94% | ||
| GM | 83% | ||
| FCFM | 58.76% |
ROA(3y)6.94%
ROA(5y)4.44%
ROE(3y)9.26%
ROE(5y)6.02%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y181.33%
ROICexgc growth 5YN/A
ROICexc growth 3Y154.84%
ROICexc growth 5YN/A
OM growth 3Y48.45%
OM growth 5YN/A
PM growth 3Y14.46%
PM growth 5YN/A
GM growth 3Y18.94%
GM growth 5Y6.74%
F-Score8
Asset Turnover0.41
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0.01 | ||
| Debt/EBITDA | 0.01 | ||
| Cap/Depr | 46.02% | ||
| Cap/Sales | 2.12% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 100.77% | ||
| Profit Quality | 117.65% | ||
| Current Ratio | 4.19 | ||
| Quick Ratio | 3.91 | ||
| Altman-Z | 5.8 |
F-Score8
WACC7.68%
ROIC/WACC2.81
Cap/Depr(3y)45.29%
Cap/Depr(5y)77.05%
Cap/Sales(3y)4.67%
Cap/Sales(5y)8.07%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)1315.29%
EPS 3Y85.2%
EPS 5YN/A
EPS Q2Q%551.15%
EPS Next Y-23.67%
EPS Next 2Y-48.85%
EPS Next 3Y-27.68%
EPS Next 5Y29.02%
Revenue 1Y (TTM)187.55%
Revenue growth 3Y60.05%
Revenue growth 5Y33.68%
Sales Q2Q%165.79%
Revenue Next Year-19.4%
Revenue Next 2Y-19.53%
Revenue Next 3Y-19.24%
Revenue Next 5Y22.67%
EBIT growth 1Y8040.37%
EBIT growth 3Y137.59%
EBIT growth 5YN/A
EBIT Next Year-33.52%
EBIT Next 3Y-14.79%
EBIT Next 5Y28.59%
FCF growth 1Y756.04%
FCF growth 3Y236.69%
FCF growth 5YN/A
OCF growth 1Y615.22%
OCF growth 3Y134.4%
OCF growth 5YN/A
COSMO PHARMACEUTICALS NV / C43.DE FAQ
What is the ChartMill fundamental rating of COSMO PHARMACEUTICALS NV (C43.DE) stock?
ChartMill assigns a fundamental rating of 9 / 10 to C43.DE.
What is the valuation status of COSMO PHARMACEUTICALS NV (C43.DE) stock?
ChartMill assigns a valuation rating of 8 / 10 to COSMO PHARMACEUTICALS NV (C43.DE). This can be considered as Undervalued.
How profitable is COSMO PHARMACEUTICALS NV (C43.DE) stock?
COSMO PHARMACEUTICALS NV (C43.DE) has a profitability rating of 8 / 10.
Can you provide the PE and PB ratios for C43 stock?
The Price/Earnings (PE) ratio for COSMO PHARMACEUTICALS NV (C43.DE) is 5.98 and the Price/Book (PB) ratio is 1.72.
Can you provide the financial health for C43 stock?
The financial health rating of COSMO PHARMACEUTICALS NV (C43.DE) is 9 / 10.